TY - JOUR T1 - Distribution of lifespan gain from primary prevention intervention JF - Open Heart JO - Open Heart DO - 10.1136/openhrt-2015-000343 VL - 3 IS - 1 SP - e000343 AU - Judith A Finegold AU - Matthew J Shun-Shin AU - Graham D Cole AU - Saman Zaman AU - Annette Maznyczka AU - Sameer Zaman AU - Rasha Al-Lamee AU - Siqin Ye AU - Darrel P Francis Y1 - 2016/03/01 UR - http://openheart.bmj.com/content/3/1/e000343.abstract N2 - Objective When advising patients about possible initiation of primary prevention treatment, clinicians currently do not have information on expected impact on lifespan, nor how much this increment differs between individuals.Methods First, UK cardiovascular and non-cardiovascular mortality data were used to calculate the mean lifespan gain from an intervention (such as a statin) that reduces cardiovascular mortality by 30%. Second, a new method was developed to calculate the probability distribution of lifespan gain. Third, we performed a survey in three UK cities on 11 days between May–June 2014 involving 396 participants (mean age 40 years, 55% male) to assess how individuals evaluate potential benefit from primary prevention therapies.Results Among numerous identical patients, the lifespan gain, from an intervention that reduces cardiovascular mortality by 30%, is concentrated within an unpredictable minority. For example, men aged 50 years with national average cardiovascular risk have mean lifespan gain of 7 months. However, 93% of these identical individuals gain no lifespan, while the remaining 7% gain a mean of 99 months. Many survey respondents preferred a chance of large lifespan gain to the equivalent life expectancy gain given as certainty. Indeed, 33% preferred a 2% probability of 10 years to fivefold more gain, expressed as certainty of 1 year.Conclusions People who gain lifespan from preventative therapy gain far more than the average for their risk stratum, even if perfectly defined. This may be important in patient decision-making. Looking beyond mortality reduction alone from preventative therapy, the benefits are likely to be even larger. ER -